5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      IL-17A inhibitions of indole alkaloids from traditional Chinese medicine Qing Dai

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ethnopharmacological relevance

          Qing Dai, a famous traditional Chinese medicine (TCM), is prepared by a traditional fermentation process with the aerial part of Strobilanthes cusia. Currently, this TCM could treat various clinical inflammatory diseases, such as ulcerative colitis and psoriasis, however, the bioactive components of Qing Dai are unknown clearly.

          Aim of the study

          To isolate and identify the anti-IL-17A components of Qing Dai.

          Materials and methods

          Silica, RP-18 gels, and size exclusion resin were used for column chromatography to isolate the pure compounds. The structures of isolates were elucidated by NMR, MS, UV, IR spectra, and optical rotation. IL-17A protein and gene expressions were also evaluated in the Th17 cell model and luciferase reporter assay, respectively.

          Results

          Two indole alkaloids, including one new indigodole D and cephalandole B, were isolated from Qing Dai. Indigodole D could inhibit IL-17A protein production during the Th17 polarization (EC 50: 2.16 μg/mL) or after the polarization (EC 50: 5.99 μg/mL) without cytotoxicity toward Th17 cells. Cephalandole B did not inhibit the IL-17A protein secretion. Nevertheless, both isolates notably inhibited IL-17A gene expression, especially cephalandole B, in a dose-dependent manner in Jukat cells with IL-17A luciferase reporter.

          Conclusions

          Indole alkaloids, indigodoles A, C, D, tryptanthrin, and indirubin could contribute to anti-IL 17A properties of Qing Dai. The possible biogenetic mechanisms of above-mentioned indoles were also speculated in this investigation for further promising anti-IL-17 lead drugs development.

          Graphical abstract

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

          STAT3 activation has been observed in several autoimmune diseases, suggesting that STAT3-mediated pathways promote pathologic immune responses. We provide in vivo evidence that the fundamental role of STAT3 signaling in autoimmunity relates to its absolute requirement for generating T(H)17 T cell responses. We show that STAT3 is a master regulator of this pathogenic T cell subtype, acting at multiple levels in vivo, including T(H)17 T cell differentiation and cytokine production, as well as induction of RORgamma t and the IL-23R. Neither naturally occurring T(H)17 cells nor T(H)17-dependent autoimmunity occurs when STAT3 is ablated in CD4 cells. Furthermore, ablation of STAT3 signaling in CD4 cells results in increased T(H)1 responses, indicating that STAT3 signaling skews T(H) responses away from the T(H)1 pathway and toward the T(H)17 pathway. Thus, STAT3 is a candidate target for T(H)17-dependent autoimmune disease immunotherapy that could selectively inhibit pathogenic immune pathways.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Tc17 CD8 T cells: functional plasticity and subset diversity.

            IL-17-secreting CD8 T cells (Tc17) have been described in several settings, but little is known regarding their functional characteristics. While Tc1 cells produced IFN-gamma and efficiently killed targets, Tc17 cells lacked lytic function in vitro. Interestingly, the small numbers of IFN-gamma-positive or IL-17/IFN-gamma-double-positive cells generated under Tc17 conditions also lacked lytic activity and expressed a similar pattern of cell surface proteins to IL-17-producing cells. As is the case for Th17 (CD4) cells, STAT3 is important for Tc17 polarization, both in vitro and in vivo. Adoptive transfer of highly purified, Ag-specific IL-17-secreting Tc17 cells into Ag-bearing hosts resulted in near complete conversion to an IFN-gamma-secreting phenotype and substantial pulmonary pathology, demonstrating functional plasticity. Tc17 also accumulated to a greater extent than did Tc1 cells, suggesting that adoptive transfer of CD8 T cells cultured in Tc17 conditions may have therapeutic potential for diseases in which IFN-gamma-producing cells are desired.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Modulation of anti-tumor immunity by the brain’s reward system

              Regulating immunity is a leading target for cancer therapy. Here, we show that the anti-tumor immune response can be modulated by the brain’s reward system, a key circuitry in emotional processes. Activation of the reward system in tumor-bearing mice (Lewis lung carcinoma (LLC) and B16 melanoma) using chemogenetics (DREADDs), resulted in reduced tumor weight. This effect was mediated via the sympathetic nervous system (SNS), manifested by an attenuated noradrenergic input to a major immunological site, the bone marrow. Myeloid derived suppressor cells (MDSCs), which develop in the bone marrow, became less immunosuppressive following reward system activation. By depleting or adoptively transferring the MDSCs, we demonstrated that these cells are both necessary and sufficient to mediate reward system effects on tumor growth. Given the central role of the reward system in positive emotions, these findings introduce a physiological mechanism whereby the patient’s psychological state can impact anti-tumor immunity and cancer progression.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Ethnopharmacol
                J Ethnopharmacol
                Journal of Ethnopharmacology
                Elsevier B.V.
                0378-8741
                1872-7573
                16 March 2020
                12 June 2020
                16 March 2020
                : 255
                : 112772
                Affiliations
                [a ]Department of Cosmeceutics, China Medical University, Taichung, 40402, Taiwan
                [b ]Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, 40447, Taiwan
                [c ]Chinese Medicine Research Center, China Medical University, Taichung, 40402, Taiwan
                [d ]Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, 40402, Taiwan
                [e ]Department of Biotechnology, Asia University, Taichung, 41354, Taiwan
                [f ]Graduate Institute of Chinese Medicine, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan
                [g ]Department of Chinese Medicine, China Medical University Hospital, Taichung, 40447, Taiwan
                [h ]Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, 40447, Taiwan
                [i ]Graduate Institute of Integrated Medicine, China Medical University, Taichung, 40402, Taiwan
                [j ]Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, 40447, Taiwan
                Author notes
                []Corresponding author. Department of Cosmeceutics, China Medical University, Taichung, 40402, Taiwan. chlilee@ 123456mail.cmu.edu.tw
                Article
                S0378-8741(19)33489-0 112772
                10.1016/j.jep.2020.112772
                7156250
                32194230
                c0552f3f-4f66-4cfd-a9e5-c8ee118e8605
                © 2020 Elsevier B.V. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 3 September 2019
                : 5 March 2020
                : 15 March 2020
                Categories
                Article

                Pharmacology & Pharmaceutical medicine
                qing dai,strobilanthes cusia,indigodole d,indole alkaloids,il-17a inhibition

                Comments

                Comment on this article